Onyx Pharmaceuticals Announces Teleconference And Webcast To Discuss Nexavar® Approval

Contact:
Julie Wood
510-597-6505

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss the approval of Nexavar^® (sorafenib) tablets.  The teleconference is scheduled for Tuesday, December 20, 2005, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). 

Interested parties may access a live webcast of the presentation at:

http://audioevent.mshow.com/273506/

or by dialing (706) 758-9355 and using the conference ID 3546177.  A replay of the presentation will be available on the Onyx website or by dialing (706) 645-9291 and using the conference ID 3546177 approximately two hours after the teleconference concludes.  The replay will be available through January 20, 2006. 

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer.  With its collaborators, the company is developing small molecule drugs, including Nexavar with Bayer Pharmaceuticals Corporation.   For more information about Onyx’s pipeline and activities, visit the company’s website at www.onyx-pharm.com.

Nexavar^® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Back to 2005 Press Releases